

Amendments to the Specification:

Please amend the paragraph at page 14 of the instant specification as follows:

As a result of administration of [[g39]]CD40L antagonist, it was confirmed that production of the anti-Dsg antibody was suppressed as well as the skin and mucosal lesions due to pemphigus were ameliorated. Therefore, it was shown that a CD40L antagonist could serve as a fundamental remedy and a preventive agent for pemphigus.